These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36528652)

  • 1. USP5-Beclin 1 axis overrides p53-dependent senescence and drives Kras-induced tumorigenicity.
    Li J; Wang Y; Luo Y; Liu Y; Yi Y; Li J; Pan Y; Li W; You W; Hu Q; Zhao Z; Zhang Y; Cao Y; Zhang L; Yuan J; Xiao ZJ
    Nat Commun; 2022 Dec; 13(1):7799. PubMed ID: 36528652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
    Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
    PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.
    Baek KH; Bhang D; Zaslavsky A; Wang LC; Vachani A; Kim CF; Albelda SM; Evan GI; Ryeom S
    J Clin Invest; 2013 Oct; 123(10):4375-89. PubMed ID: 24018559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer.
    Morton JP; Timpson P; Karim SA; Ridgway RA; Athineos D; Doyle B; Jamieson NB; Oien KA; Lowy AM; Brunton VG; Frame MC; Evans TR; Sansom OJ
    Proc Natl Acad Sci U S A; 2010 Jan; 107(1):246-51. PubMed ID: 20018721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS
    Li S; Liu S; Deng J; Akbay EA; Hai J; Ambrogio C; Zhang L; Zhou F; Jenkins RW; Adeegbe DO; Gao P; Wang X; Paweletz CP; Herter-Sprie GS; Chen T; Gutiérrez-Quiceno L; Zhang Y; Merlino AA; Quinn MM; Zeng Y; Yu X; Liu Y; Fan L; Aguirre AJ; Barbie DA; Yi X; Wong KK
    Clin Cancer Res; 2018 Oct; 24(19):4854-4864. PubMed ID: 29945997
    [No Abstract]   [Full Text] [Related]  

  • 6. Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis.
    Chibaya L; Karim B; Zhang H; Jones SN
    Proc Natl Acad Sci U S A; 2021 Jan; 118(4):. PubMed ID: 33468664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2.
    Kim D; Min D; Kim J; Kim MJ; Seo Y; Jung BH; Kwon SH; Ro H; Lee S; Sa JK; Lee JY
    J Exp Clin Cancer Res; 2023 Dec; 42(1):338. PubMed ID: 38093368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner.
    Meinhardt AL; Munkhbaatar E; Höckendorf U; Dietzen M; Dechant M; Anton M; Jacob A; Steiger K; Weichert W; Brcic L; McGranahan N; Branca C; Kaufmann T; Dengler MA; Jost PJ
    Oncogene; 2022 Feb; 41(9):1376-1382. PubMed ID: 35091677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.
    Okayama H; Saito M; Oue N; Weiss JM; Stauffer J; Takenoshita S; Wiltrout RH; Hussain SP; Harris CC
    Int J Cancer; 2013 Jan; 132(1):9-18. PubMed ID: 22618808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways.
    Patel A; Burton DG; Halvorsen K; Balkan W; Reiner T; Perez-Stable C; Cohen A; Munoz A; Giribaldi MG; Singh S; Robbins DJ; Nguyen DM; Rai P
    Oncogene; 2015 May; 34(20):2586-96. PubMed ID: 25023700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis.
    Hill KS; Erdogan E; Khoor A; Walsh MP; Leitges M; Murray NR; Fields AP
    Oncogene; 2014 Apr; 33(16):2134-44. PubMed ID: 23604119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated FBXL6 activates both wild-type KRAS and mutant KRAS
    Xiong HJ; Yu HQ; Zhang J; Fang L; Wu D; Lin XT; Xie CM
    Mil Med Res; 2023 Dec; 10(1):68. PubMed ID: 38124228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.
    Cisowski J; Sayin VI; Liu M; Karlsson C; Bergo MO
    Oncogene; 2016 Mar; 35(10):1328-33. PubMed ID: 26028035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
    Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
    Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
    [No Abstract]   [Full Text] [Related]  

  • 15. YTHDF1 Promotes Cyclin B1 Translation through m
    Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
    Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation Of Wild-Type Hras Suppresses The Earliest Stages Of Pancreatic Cancer.
    Weyandt J
    Redox Biol; 2015 Aug; 5():414. PubMed ID: 28162272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.
    Kasinski AL; Slack FJ
    Cancer Res; 2012 Nov; 72(21):5576-87. PubMed ID: 22964582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer.
    Miller P; Akama-Garren EH; Owen RP; Demetriou C; Carroll TM; Slee E; Al Moussawi K; Ellis M; Goldin R; O'Neill E; Lu X
    Cell Death Differ; 2023 Jul; 30(7):1619-1635. PubMed ID: 37270580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose-6-phosphate dehydrogenase maintains redox homeostasis and biosynthesis in LKB1-deficient KRAS-driven lung cancer.
    Lan T; Arastu S; Lam J; Kim H; Wang W; Wang S; Bhatt V; Lopes EC; Hu Z; Sun M; Luo X; Ghergurovich JM; Su X; Rabinowitz JD; White E; Guo JY
    Nat Commun; 2024 Jul; 15(1):5857. PubMed ID: 38997257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.